This study was specific to IDH-mutant tumors and revealed a novel mechanism for how PDGFRA (a growth factor receptor) gets overexpressed in these tumors.
"The research suggests that treating gliomas as soon as they are detected with a drug like 5-Azacytidine can restore the DNA loops, Dr. Bernstein said."
Stephen wasn't 5-Azacytidine (Vidaza) already used on IDH1 mutant gliomas few years ago? My thought on this article is that if Vidaza is so promising, why didn't continue with the studies few years ago
Also, Dr. Bernstein was kind enough to send me the article on this matter (Insulator dysfunction and oncogene activation inIDH mutant gliomas), I sent it to Stephen so he can upload it to the library.
Yes I have this study, as well as an editorial summary of it, and I will upload to the library in the Pathology folder.
Yes, 5-azacytidine was used in a Johns Hopkins study a couple years ago in a subcutaneous IDH1-mutant astrocytoma mouse model. At the time, Greg Riggins said they would be trying to get this into trial as quickly as possible, but it hasn't happened yet. Keep in mind that study was not intracranial, so was not providing proof of blood-brain barrier penetration, which is a big stumbling block to successful clinical translation of preclinical work.
Thanks Anna!
ReplyDeleteThis study was specific to IDH-mutant tumors and revealed a novel mechanism for how PDGFRA (a growth factor receptor) gets overexpressed in these tumors.
ReplyDelete"The research suggests that treating gliomas as soon as they are detected with a drug like 5-Azacytidine can restore the DNA loops, Dr. Bernstein said."
ReplyDeleteStephen wasn't 5-Azacytidine (Vidaza) already used on IDH1 mutant gliomas few years ago? My thought on this article is that if Vidaza is so promising, why didn't continue with the studies few years ago
Also, Dr. Bernstein was kind enough to send me the article on this matter (Insulator dysfunction and oncogene activation inIDH mutant gliomas), I sent it to Stephen so he can upload it to the library.
DeleteYes I have this study, as well as an editorial summary of it, and I will upload to the library in the Pathology folder.
ReplyDeleteYes, 5-azacytidine was used in a Johns Hopkins study a couple years ago in a subcutaneous IDH1-mutant astrocytoma mouse model. At the time, Greg Riggins said they would be trying to get this into trial as quickly as possible, but it hasn't happened yet. Keep in mind that study was not intracranial, so was not providing proof of blood-brain barrier penetration, which is a big stumbling block to successful clinical translation of preclinical work.